Overview

Levosimendan in High Risk Patients Undergoing Cardiac Surgery

Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Low cardiac output syndrome (LCOs) is a serious complication in critically ill patients or those undergoing major surgery, resulting in multiple organ damage with significant in-hospital and long-term morbidity and mortality, as well as prolonged hospital stay. In this setting the mortality rate is distressingly high despite improvements in intensive care treatment, but survivors have an acceptable quality of life.
Phase:
Phase 4
Details
Lead Sponsor:
Università Vita-Salute San Raffaele
Treatments:
Simendan